{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:44:33Z","timestamp":1792496673265,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K11907"],"award-info":[{"award-number":["24K11907"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26K19594"],"award-info":[{"award-number":["26K19594"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ajpath.2026.08.005","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:56:34Z","timestamp":1790060194000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement Factor B Blockade by Iptacopan Drives Antitumor Complement-Based Immunomodulation in Pancreatic Cancer Microenvironment"],"prefix":"10.1016","author":[{"given":"Daren","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6495-0422","authenticated-orcid":false,"given":"Shigetsugu","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Sogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Moriyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Takayashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2026.08.005_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajpath.2026.08.005_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ajpath.2026.08.005_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1101\/gad.351863.124","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"39","author":"Ying","year":"2025","journal-title":"Genes Dev"},{"key":"10.1016\/j.ajpath.2026.08.005_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41416-025-03260-6","article-title":"Complement system in tumor growth and metastases","volume":"134","author":"Borisov","year":"2026","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2026.08.005_bib5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2026.08.005_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.imlet.2015.02.009","article-title":"Complement receptor type 1 (CR1\/CD35) expressed on activated human CD4+ T cells contributes to generation of regulatory T cells","volume":"164","author":"T\u00f6r\u00f6k","year":"2015","journal-title":"Immunol Lett"},{"key":"10.1016\/j.ajpath.2026.08.005_bib7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymthe.2023.12.010","article-title":"Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8+ T cell activity","volume":"32","author":"Luan","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajpath.2026.08.005_bib8","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/s41416-025-03185-0","article-title":"Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma","volume":"133","author":"Eto","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2026.08.005_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I\u2014molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajpath.2026.08.005_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: role in immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajpath.2026.08.005_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s13402-021-00614-z","article-title":"Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer","volume":"44","author":"Shimazaki","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.ajpath.2026.08.005_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1477-5956-12-32","article-title":"Inflammation: an important parameter in the search of prostate cancer biomarkers","volume":"12","author":"Bergamini","year":"2014","journal-title":"Proteome Sci"},{"key":"10.1016\/j.ajpath.2026.08.005_bib13","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.4049\/jimmunol.2000511","article-title":"Complement as prognostic biomarker and potential therapeutic target in renal cell carcinoma","volume":"205","author":"Reese","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.ajpath.2026.08.005_bib14","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2026.08.005_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2026.08.005_bib16","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2026.08.005_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.ajpath.2026.08.005_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13046-021-02019-0","article-title":"C4b-binding protein [alpha]-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer","volume":"40","author":"Sasaki","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2026.08.005_bib19","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-07-0842","article-title":"CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer","volume":"13","author":"Kiniwa","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2026.08.005_bib20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/cmi.2015.57","article-title":"Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment","volume":"12","author":"Zhang","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ajpath.2026.08.005_bib21","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/bph.16313","article-title":"The impact of Foxp3+ regulatory T-cells on CD8+ T-cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors","volume":"183","author":"Attias","year":"2026","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ajpath.2026.08.005_bib22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","article-title":"Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2026.08.005_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ajpath.2026.08.005_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ajpath.2026.08.005_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2326-6066.CIR-24-0250","article-title":"The C5a\/C5aR1 axis promotes migration of tolerogenic dendritic cells to lymph nodes, impairing the anticancer immune response","volume":"13","author":"Senent","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ajpath.2026.08.005_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/gut.2008.158824","article-title":"Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue","volume":"58","author":"Chaput","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2026.08.005_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2026.08.005_bib28","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2026.08.005_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/tgh.2020.04.03","article-title":"Pancreatic cancer and immune checkpoint inhibitors\u2014still a long way to go","volume":"6","author":"Bian","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.08.005_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1349587","article-title":"Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1\/PD-L1 blockade","volume":"6","author":"Zha","year":"2017","journal-title":"Oncoimmunology"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944026002579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944026002579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:36:39Z","timestamp":1792496199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944026002579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S0002944026002579"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2026.08.005","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement Factor B Blockade by Iptacopan Drives Antitumor Complement-Based Immunomodulation in Pancreatic Cancer Microenvironment","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2026.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Investigative Pathology.","name":"copyright","label":"Copyright"}]}}